J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1855-1859. doi: 10.1016/j.japh.2022.08.012. Epub 2022 Aug 21.
Diabetes is a complicated health condition that can lead to significant health complications. Pharmacists are in an ideal position to make therapeutic interventions, provide clinical education, and can provide necessary follow-up to evaluate response to therapy for patients with diabetes.
The primary objective of this study is to evaluate the mean change in hemoglobin A1c (HbA1c) in patients receiving short-term diabetes management services from a clinical pharmacist through collaborative drug therapy management.
This study is a single-center retrospective chart review of patients with diabetes who have been referred by their endocrinologist to the clinical pharmacist for short-term intensification of pharmacologic management of hyperglycemia. Patients included in the study completed at least 2 visits with the pharmacist during the study period. The primary outcome was to evaluate the mean absolute change in HbA1c at 3-6 months from baseline.
Data were collected from 117 patients. The average age was 55 years (19-91 years, SD ± 14.5), 65 patients (55.6%) were female, average duration of diabetes was 14.9 years (0.5-49 years, SD ± 9.9), 21 patients (17.9%) had type 1 diabetes, 96 patients (82.1%) had type 2 diabetes, and 88 patients (75.2%) had a baseline HbA1c of at least 8.5%. On average, patients reduced their HbA1c by 2.0% (P < 0.001) at 3-6 months. For patients with a baseline HbA1c of at least 8.5%, they experienced a 2.5% (P < 0.001) reduction in HbA1c at 3-6 months.
The addition of a clinical pharmacist within the endocrinology practice was associated with significant improvements in glycemic control for those referred. This short-term, intensive service model demonstrates that patients can achieve significant reductions in HbA1c with temporary support from a clinical pharmacist.
糖尿病是一种复杂的健康状况，可导致严重的健康并发症。药剂师处于理想的位置，可以进行治疗干预、提供临床教育，并为糖尿病患者提供必要的后续治疗以评估治疗反应。
本研究的主要目的是评估通过临床药师进行协作药物治疗管理，为接受短期糖尿病管理服务的患者的血红蛋白 A1c（HbA1c）平均变化。
这是一项对因高血糖症进行药物强化管理而由内分泌科医生转介给临床药师的糖尿病患者的单中心回顾性图表研究。在研究期间，患者完成了至少 2 次与药剂师的就诊。主要结局是评估从基线到 3-6 个月时 HbA1c 的平均绝对变化。
共收集了 117 名患者的数据。患者平均年龄为 55 岁（19-91 岁，标准差±14.5），65 名患者（55.6%）为女性，糖尿病平均病程为 14.9 年（0.5-49 年，标准差±9.9），21 名患者（17.9%）患有 1 型糖尿病，96 名患者（82.1%）患有 2 型糖尿病，88 名患者（75.2%）的基线 HbA1c 至少为 8.5%。平均而言，患者在 3-6 个月时 HbA1c 降低了 2.0%（P<0.001）。对于基线 HbA1c 至少为 8.5%的患者，他们在 3-6 个月时 HbA1c 降低了 2.5%（P<0.001）。
在内分泌科实践中增加临床药师可显著改善转介患者的血糖控制。这种短期强化服务模式表明，患者在临床药师的临时支持下可以显著降低 HbA1c。
